PRA Health Sciences
Company typeSubsidiary
Nasdaq: PRAH
IndustryPharmaceuticals & Biotechnology
Founded1976; 48 years ago (1976)
Charlottesville, Virginia, U.S.
Headquarters
Raleigh, North Carolina
,
U.S.
Area served
Worldwide
Key people
Colin Shannon (President and CEO)
Revenue
  • Increase US$ 1.948 billion (2017)[1]
  • Increase US$ 1.580 billion (2016) [1]
Number of employees
17,000+[1]
ParentICON plc
Websiteprahs.com

PRA Health Sciences was a contract research organization (CRO) with headquarters in Raleigh, North Carolina. It was established in 1976 and acquired by ICON in 2021.

Background

PRA was founded as the Anti-Inflammatory Drug Study Group in 1976, renamed PRA in 1982, as it expanded into other therapeutic areas besides inflammation.[2] In 2013 the company was acquired by Kohlberg Kravis Roberts, which brought the company public in November 2014 and maintained shares until September 2019.[3] In August 2017, the company acquired Conshohocken-based real-world healthcare data, analytics, and technology solutions company Symphony Health for US$530 million.[4] PRA's 2018 revenue was US$2.87 billion.[5] PRA was acquired by ICON PLC on 1 July 2021.[6]

References

  1. ^ a b c "PRA 10-K For the fiscal year ended December 31, 2017". PRA Health Sciences via SEC Edgar. 2018-02-02. See SEC Edgar index page for PRA for updates
  2. ^ "PRA Health Sciences becomes latest big CRO to launch IPO". CenterWatch News Online. 13 November 2014.
  3. ^ "PRA Health Sciences Announces Secondary Offering and Concurrent Share Repurchase". Globenewswire. September 3, 2019.
  4. ^ Liu, Angus (August 8, 2017). "PRA Health Sciences makes $530M Symphony buy, reports 16% revenue growth in Q2". FierceBiotech.
  5. ^ "Investors | ICON PLC".
  6. ^ "ICON acquisition creates world-leading healthcare intelligence and clinical research organisation" (Press release). 1 July 2021.

External links

Contract research organization
Authority control databases
Categories